Latest Content

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, stated that preparing optometric students for the possibility of burnout may help reduce its prevalence.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her AOA Optometry's Meeting 2026 session.

Alcon's TikTok, YouTube, and Instagram campaign uses creator-led patient stories to reintroduce LASIK to younger consumers and prompt conversations with surgeons.

Erin Rueff, OD, PhD, FAAO, provides tips to fellow clinicians on how to keep these patients comfortable in their lenses.

Healome’s proprietary eye drop-matrix behaves like a liquid when it is dropped on the eye, and then restructures on the ocular surface to form a clear, lubricating, protective matrix that can deliver a broad range of drugs.

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop, for the treatment of presbyopia in adults.

As of July 13, 2026, a meeting date has not been set.

Screen time's derailing of the circadian rhythm could contribute to behavioral difficulties in pediatric patients.

The FDA issued a nationwide recall of a steroid eye drop.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her session on the hormonal and aesthetic considerations ODs should make when treating these patients.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.